Drugs / Ledipasvir-Sofosbuvir
Ledipasvir-Sofosbuvir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02660905 | Apr 2016 → Jan 2018 | HIV infectious disease, chronic hepatitis C virus infection | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05091008 Comparator | Mar 2018 → Aug 2019 | chronic hepatitis C virus infection | Mansoura University Children Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ledipasvir-Sofosbuvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05091008 ↗ |
| Known as | LPV-SOF | “The availability of interferon (IFN)-free HCV Direct Acting Antiviral (DAA) antiviral therapy such as Ledipasvir-Sofosbuvir (LPV-SOF) allows for broad provision of treatment...” NCT02660905 ↗ |
| Known as | Sofosbuvir/ Ledipasvir | “This study aims to evaluate the safety and efficacy of the combined Sofosbuvir/ Ledipasvir regimen given for 12 weeks in children aged 12-18 years or weighing at least 35 kg...” NCT05091008 ↗ |
| Route | Oral | “taken orally once daily” NCT05091008 ↗ |